MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
17.77
-0.32
-1.77%
After Hours: 18.07 +0.3 +1.69% 19:33 01/02 EST
OPEN
18.35
PREV CLOSE
18.09
HIGH
19.08
LOW
17.64
VOLUME
111.21K
TURNOVER
--
52 WEEK HIGH
19.08
52 WEEK LOW
5.01
MARKET CAP
128.13M
P/E (TTM)
8.10
1D
5D
1M
3M
1Y
5Y
1D
Atara revises tab-cel commercialization milestones with Pierre Fabre
TipRanks · 11h ago
ATARA BIOTHERAPEUTICS INC - MILESTONE PAYMENTS REDUCED FROM $40 MLN TO $31 MLN - SEC FILING
Reuters · 12h ago
Atara Biotherapeutics Amends Pierre Fabre Agreement to Adjust Milestone Payments
Reuters · 12h ago
Biotech Stocks Facing FDA Decision In January 2026
NASDAQ · 12/30/2025 08:21
Weekly Report: what happened at ATRA last week (1222-1226)?
Weekly Report · 12/29/2025 10:15
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 12/23/2025 12:05
Weekly Report: what happened at ATRA last week (1215-1219)?
Weekly Report · 12/22/2025 10:15
Atara Biotherapeutics Price Target Raised to $25.00/Share From $17.00 by Canaccord Genuity
Dow Jones · 12/19/2025 15:12
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.